The Medical Advisor

Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against ...

Introduction: The Rise of Metabolic Therapy in Cancer Care The field of oncology is generally based on three treatment areas: medical oncology, radiation oncology, and surgical oncology. However, another area is looming on the horizon, quickly gaining traction as a new and exciting frontier of cancer treatment. Metabolic oncology, also known as cancer metabolism, focuses on how cancer cells use energy and nutrients differently than normal cells. Scientists working in metabolic oncology look for targets in these metabolic processes to create treatments that can specifically attack cancer cells while protecting healthy cells. A  2026 large-scale population study  published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis: Metabolic dysfunction is not merely a comorbidity — it may be a centra...